Pure CBD is not internationally controlled
The INCB’s 2026 notice states that pure CBD is not controlled under the international drug control conventions.
Patients. Evidence. Rights.
Care Before Discrimination.
CBD is a Human Right.
European governments are being urged to restrict CBD as a “drug precursor” — a claim not supported by the currently available evidence, advanced without public debate. We are an open coalition of patient organisations. We ask for transparent, evidence-based decisions and proportionate regulation — not covert prohibition.
- Open patient coalition
- Evidence-based
- International
The current threat
A precursor claim the evidence does not carry.
The INCB’s own notice concedes the precursor evidence is “limited” — and notes that pure CBD is not controlled under the international drug control conventions.
INCB · PP Notice No. 1/2026, 24 Feb 2026
Following an internal INCB notification (PP Notice No. 1/2026) and China’s 2024 designation of CBD as a drug precursor, the Czech government has moved a proposal to restrict CBD on “precursor” grounds into its inter-ministerial comment procedure — an administrative path, without open public debate. If one member state converts this framing into law, others primed by the same notice may follow.
The record
What the evidence says
The INCB notice says the evidence is “limited”
The same notice concedes the evidence for CBD’s use as a starting material is “limited”.
Restricting CBD won’t stop synthetic molecules
The dangerous “spice” cannabinoids are made from industrial chemicals, not CBD. Banning CBD would not remove them from the market — it would only strip patients of tested, quality-controlled CBD.
What we ask
Six demands. None of them radical.
The coalition does not argue that CBD should be unregulated. We argue that restrictions must not be introduced covertly, administratively, or on evidence that does not withstand scrutiny.
-
Publish the evidence.
A full, transparent assessment of the scientific record before any restriction is proposed or adopted.
-
No covert restrictions.
No administrative measures without open public debate, a proportionality test, and a patient-impact assessment.
-
Respect autonomy and dignity.
Patients’ right to make informed, evidence-based decisions about their own treatment.
-
Regulate, don’t prohibit.
Proportionate rules: quality standards, contaminant testing, clear labelling, age restrictions where relevant.
-
Act on the real threat.
Enforcement against synthetic cannabinoids sold as “collector’s items” — not against tested products patients rely on.
-
A seat at the table.
Patient organisations formally consulted in every decision that affects access to treatment.
Patient voices
The people a restriction would actually reach
Real patients, in their own words and with their written consent — people living with cancer, multiple sclerosis, chronic pain and more, for whom lawful CBD is part of daily care.
“CBD helped me through chemotherapy without ever clouding my mind.”
“CBD is not a miracle cure, but it helps me get through daily life with MS a little better.”
Your story can change this debate
If CBD is part of how you manage your health, and you are willing to tell that story — named or anonymised — write to coalition@cbdhumanright.org. We will explain the consent process before anything is recorded.
We hold ourselves to the standard we demand.
This campaign asks governments to decide transparently. The same rules apply to us: we will publish our funding and independence policy, we name our coalition members, and we process patient data only with explicit consent and only for this appeal.
-
Verified signatures
Signatures are verified by independent moderators.
-
Patient organisations
Led by patient groups across Europe.
-
Transparent campaign governance
Decisions, funding and processes will be publicly disclosed.
Add your name to the appeal
An open call from an international coalition of patient organisations. Sign as a citizen, patient, carer, or healthcare professional — or ask your organisation to join.
Sign the appeal- Aube (Canada)
- Centrum Paraple (Czech Republic)
- Dosemociones (Spain)
- Fuck Cancer (Czech Republic)
- KOPAC (Czech Republic)
- Associação Mães Pela Cannabis (Portugal)
- PatientsCann (United Kingdom)
- Verein Medcan (Switzerland)
Supported by
- Asociace bezpečného konopí (Safe Cannabis Association) (Czech Republic · Industry association)
- HARP (Human Application Research Program)
- RARE (Racionální regulace) (Czech Republic · NGO)
These organisations support the appeal. The coalition that issues it is made up of patient organisations (above).
Further patient organisations and individuals may join at any time — the appeal is an open call.
